Top NYC, NY Biotech Companies With Best Stability & Growth (130)
Click Therapeutics, Inc., develops, validates, and commercializes software as prescription medical treatments for people with unmet medical needs. As a leading innovator of Digital Therapeutics™, Click delivers accessible, clinically proven, FDA-regulated prescription treatments to the smartphone in your hand. Click’s treatments are defined by a commitment to applying technical and scientific rigor and patient-centric design to the development process. This...
Click Therapeutics's Top Stability, Growth & Resilience Strengths
Strategic Partnerships: Long‑running collaborations with Boehringer Ingelheim and Otsuka, plus a 2025 strategic investment from Dassault Systèmes/Medidata, reinforce scale and credibility. Evidence suggests these alliances provide development resources, commercialization pathways, and platform reach.
Product Line Growth: Multiple FDA authorizations (Rejoyn for MDD; CT‑132 for preventive episodic migraine) and the acquisition of AspyreRx expand the portfolio across psychiatry, neurology, and cardiometabolic care. Late‑stage CT‑155 Phase 3 success and Breakthrough Device status add pipeline depth.
Investor Backing & Capital Strength: Recent fundraising and M&A momentum amid a consolidating market indicate access to capital and financial resilience. This capital base supports evidence generation, scaling, and entry into new categories.
Schrödinger is a leading provider of advanced molecular simulations and enterprise software solutions and services for pharmaceutical, biotechnology, and materials science research. The predictive power of Schrödinger's software allows scientists to accelerate their research and development, reduce research costs, and make novel discoveries.
Schrödinger, Inc.'s Top Stability, Growth & Resilience Strengths
Strong Market Position & Advantage: Broad adoption across large pharma and recognition as a leader in physics‑based discovery software indicate a durable competitive edge, reinforced by flagship tools like Glide and FEP+ with peer‑reviewed validation. Penetration across all top global pharma and sticky, long‑tenure accounts suggest standard‑tool status in discovery teams.
Strong Revenue Growth: Recent results show higher software revenue and total revenue growth in 2025, with guidance pointing to continued expansion in software ACV in 2026. Management frames software as the scaled growth engine while hosted deployments rise.
Strategic Partnerships: Large, multi‑year collaborations with major pharmas and long‑running technical work with NVIDIA support pipeline upside and platform performance. Deal structures with upfronts, milestones, and potential royalties diversify growth levers.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for...
Pfizer's Top Stability, Growth & Resilience Strengths
Strong Market Position & Advantage: Industry tallies continue to place Pfizer among the global top tier by pharmaceutical revenue and scale, with company guidance keeping it one of the largest drugmakers by sales. Leadership by platforms and global footprint is reinforced by sustained positions in major rankings and markets.
Diversified Revenue Streams: The portfolio spans vaccines (e.g., Prevnar/Prevenar, Abrysvo), cardiovascular/rare disease (Eliquis alliance, Vyndaqel), oncology (legacy brands plus Seagen assets), and anti-infectives, providing multiple contributors as COVID revenues normalize. Product mix in 2025 highlighted several sizable non-COVID franchises supporting the base business.
Future-Ready Strategy: Management emphasizes oncology expansion via the Seagen acquisition, a broad late-stage pipeline with many pivotal starts slated for 2026, and cost/operations programs to fund R&D. These actions are positioned to drive a late‑decade growth reacceleration as near-term headwinds abate.
Flatiron Health is a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients today and tomorrow. Through clinical and data science, we translate patient experiences into real-world evidence to improve treatment, inform policy, and advance research. Cancer is smart. Together, we can be smarter. Flatiron Health is an independent affiliate of the Roche Group.
Flatiron Health's Top Stability, Growth & Resilience Strengths
Strong Market Position & Advantage: Flatiron is broadly regarded as a leader in oncology-focused RWD/RWE, anchored by a deep oncology EHR footprint, regulatory-grade curation, and a long track record collaborating with regulators and major biopharma. Frequent large-scale dataset releases and sustained presence at major congresses (e.g., ASCO 2025) reinforce this standing.
Strategic Partnerships: FDA has repeatedly partnered with Flatiron on oncology RWE methods and endpoints with renewals/expansions, and collaborations with leading organizations (e.g., Unicancer, Japan’s NCCHE) extend its ecosystem reach. These relationships signal methodological trust and strengthen access to high-value research opportunities.
Product Line Growth: New large-scale datasets, including six hematology cohorts covering roughly 505k patients in 2025, show continued expansion of evidence products. An active cadence of publications and presentations indicates sustained product momentum.
Formation Bio is a tech-driven pharma company differentiated by radically more efficient drug development. Formation Bio has built a technology platform that optimizes all aspects of drug development, enabling more efficient trial design, faster trial completion, and higher quality trial data capture. Formation Bio acquires clinical-stage drugs from pharma and biotech and develops them faster and more efficiently, unlocking greater...
Formation Bio's Top Stability, Growth & Resilience Strengths
Investor Backing & Capital Strength: Raised a $372M Series D in June 2024 led by Andreessen Horowitz with Sanofi participating, placing it among larger techbio financings and enabling aggressive asset licensing. Total funding above $600M and strategic capital from Sanofi signal strong financial support for scaling.
Strategic Partnerships: Entered a first-of-its-kind three-way collaboration with Sanofi and OpenAI to build AI software for drug development, indicating differentiated platform recognition. Additional marquee transactions with Sanofi (e.g., gusacitinib license) reinforce high-signal partner engagement.
Product Line Growth: Multiple sizable deals expanded and activated the portfolio, including licensing gusacitinib to Sanofi and acquiring a TYK2 inhibitor via Bleecker Bio and an oral miR-124 activator via Kenmare Bio. Public coverage cites several active clinical programs, including one in Phase 3, consistent with ongoing pipeline buildout.
At Inato, we’re on a mission to accelerate the pace of medical innovation by bringing clinical research to each and every patient, regardless of who they are and where they live. Our platform, made to connect community-based research centers to trials across the globe, aims to create greater visibility, access, and engagement across a more diverse population of doctors and...
Inato's Top Stability, Growth & Resilience Strengths
Market Expansion: Public materials highlight growth from roughly 2,500+ to 5,500–6,000+ research sites across 50+ countries and an increase to 25+ sponsors on the platform. Feedback suggests the marketplace is scaling on both the supply (sites) and demand (sponsors) sides.
Strategic Partnerships: Named collaborations with AbbVie, Sanofi, and Moderna, plus integrations with RealTime‑Devana and CRIO, demonstrate blue‑chip adoption and expanding ecosystem reach. Feedback suggests repeated use on consequential trials and data‑sharing ties are strengthening commercial durability.
Innovation-Driven Growth: Recent launches such as AI Site Selection and AI patient pre‑screening target bottlenecks in planning, site selection, and enrollment. External recognition (e.g., Fast Company’s Most Innovative Companies with adoption more than doubling in 2023) signals momentum behind product innovation.
We bring together one of the world’s largest libraries of multimodal clinical and molecular data with a robust suite of AI tools to help physicians personalize care in real time, connect patients with therapies and clinical trials, and enable partners to accelerate discovery and development of new treatments. With ~8 million de-identified research records and 350+ petabytes of data, Tempus partners...
Tempus AI's Top Stability, Growth & Resilience Strengths
Strong Revenue Growth: Reported revenue accelerated sharply year over year with continued guidance for expansion, and quarterly results showed momentum across both diagnostics and data businesses. Total remaining contract value and rising spend among existing customers support durability.
Strategic Partnerships: Multi‑year collaborations with leading biopharma and health systems, along with an international joint venture, signal deep ecosystem integration. These agreements include substantial data licensing and model‑development components that reinforce platform adoption.
Strong Market Position & Advantage: An FDA‑approved NGS companion diagnostic, broad provider reach across many U.S. academic medical centers, and a scaled multimodal oncology dataset underpin positioning as a leader in AI‑enabled precision oncology. Public‑company status and expanding trial‑matching capabilities further reinforce this standing.
Tonix Pharmaceuticals is a fully-integrated, commercial-stage biotechnology company focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA™ (cyclobenzaprine HCl sublingual tablets 2.8mg), the Company’s recently approved flagship medicine, is the first new treatment for fibromyalgia in more than 15 years. Tonix’s CNS commercial infrastructure supports its marketed products, including its acute migraine...
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit immunovant.com. For U.S. residents only.
Character Biosciences is a precision medicine company transforming drug development for progressive, polygenic diseases, beginning with ophthalmology. Our mission is to identify the genetic and molecular drivers of disease progression so we can develop targeted therapies for patients who urgently need them. We've built one of the most comprehensive resources in age-related eye diseases by partnering with over 150 ophthalmology...
PTC is a patient-centered biopharmaceutical company focused on discovering, developing & commercializing medicine for patients with rare and serious disease
The Child Mind Institute is an independent national nonprofit dedicated to transforming the lives of children and families struggling with mental health and learning disorders. Our teams work every day to deliver the highest standards of care, advance the science of the developing brain and empower parents, professionals, and policymakers to support children when and where they need it most....
Who we are: atai is a biopharmaceutical company that leverages a decentralised platform approach to incubate and accelerate the development of highly effective mental health treatments that address the unmet needs of patients. Our vision: To heal mental health disorders so that everyone, everywhere can live a more fulfilled life. Our approach: By pooling expertise, best practices, and resources across our entire portfolio, we mitigate...
Valo is a technology company built to transform the drug discovery and development process using human-centric data and AI-powered computation. Valo is fully integrating human-centric data across the entire drug development lifecycle into a single unified architecture, thereby accelerating the discovery and development of life-changing drugs while simultaneously reducing the cost, time, and failure rate. The company’s Opal Computational Platform™...
Trusted by the world's leading organizations, Point B is a consulting firm that works at the intersection of expertise, industry insight, and transformative technology. This collaborative approach enables you to solve your most important challenges, by bringing together the right mix of talent and technology to deliver greater value and impact. With over 850 associates in the US and 3000+...
LEXEO Therapeutics is a New York City-based, clinical-stage gene therapy company focused on addressing some of the most devastating genetically defined cardiovascular and central nervous system diseases affecting both larger-rare and prevalent patient populations. LEXEO’s foundational science stems from partnerships and exclusive licenses with leading academic laboratories at Weill Cornell Medical College and the University of California, San Diego, two...
Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead program, TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational, intravenous phospholipid substrate replacement therapy in development for the treatment of intestinal failure-associated liver...
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we...
Regeneron's Top Stability, Growth & Resilience Strengths
Product Line Growth: The company is growing on financials and products, with momentum attributed to EYLEA HD, Libtayo, and rising Dupixent collaboration revenue alongside shareholder-return actions (dividend and buybacks) reinforcing the trend in 2024–2025.
Future-Ready Strategy: The setup for 2025–2026 includes multiple identified catalysts, including the odronextamab FDA decision (target action date July 30, 2025), further EYLEA HD label/formulation updates, and the ongoing Dupixent COPD rollout as key determinants for sustaining or accelerating growth.
Innovation-Driven Growth: A science-driven platform approach (including VelocImmune, the Regeneron Genetics Center, and advanced proteomics/genomics) is positioned as enabling rapid therapeutic discovery across multiple therapeutic areas, supporting an ongoing pipeline-led growth thesis.
Gentueri works with laboratories to improve the quality of results and laboratory efficiency.
OnCusp Therapeutics, Inc., headquartered in New York City, is a biopharmaceutical company dedicated to transforming cutting-edge preclinical innovation into clinically validated treatments for cancer patients worldwide. OnCusp was co-founded by Dr. Bing Yuan, Dr. Eric Slosberg, and Dr. Andy Fu, and has built a strong team of accomplished veterans with proven track records in building startup biotechs, leading successful preclinical...
